Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842048 | 0.89 | DRD2 (0.41) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL342740 | 0.85 | DRD2 (0.44) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28253109 | 0.81 | TSHR (0.37) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL931670 | 0.80 | MAPT (0.48) | MEN1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL9132 | 0.80 | KDM4E (0.46) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL13835328 | 0.77 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL14120688 | 0.75 | CA12 (0.37) | TSHRNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22878 | 0.75 | TSHR (0.53) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL127000 | 0.75 | TSHR (0.65) | TSHRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL29349760 | 0.75 | TSHR (0.53) | TSHRMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3149138-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | The Procter & Gamble Company (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2015184209-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY (US) | 2015-12-03 | — | — | WO | claimed |
| US-20150344817-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY | 2015-12-03 | — | — | US | claimed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119552120-A | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112654610-B | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5712279-A | Inhibitors of microsomal triglyceride transfer protein and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996026205-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | TSHR 186/4885MEN1 4393/4885NPC1 1337/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | TSHR 2669/4885MEN1 4262/4885NPC1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.